Redcare Pharmacy: How a 60% Stock Collapse Could Pave the Way for a Digital Prescription Monopoly

Redcare Pharmacy’s shares have been crushed — down more than 60% over the past twelve months to trade near €44. That puts the stock roughly 63% below its 52-week high of €117.40. Yet beneath the wreckage, the company’s prescription-drug business is firing on all cylinders, with German e?prescription revenue surging 55% in the first quarter. The market, fixated on political headwinds and thinning margins in over?the?counter products, appears to be ignoring a dominant competitive position that could become even stronger as Germany’s pharmacy landscape undergoes its biggest shake?up in years.

Strongest Q1 in Years, Yet Shares Sink Further

Redcare’s first?quarter 2026 figures were robust by almost any measure. Group revenue climbed 18.3% to €848 million, comfortably ahead of the company’s full?year guidance of 13%–15% top?line growth. Prescription sales — which already account for the bulk of the group’s momentum — jumped 35% across all markets, with Germany alone contributing €168 million in Rx revenue. Adjusted EBITDA rose 58% to €14.4 million, reflecting early operating leverage. The active customer base expanded to 14 million. But the share price closed near €43.14 on Thursday, barely above its 50?day moving average, before nudging up 2.8% to €44.34 — a move that looks more like a dead?cat bounce than a genuine recovery.

OTC Margin Compression: The Clear and Present Danger

The primary source of the share?price pain lies in the non?prescription segment. Pharmacy chains dm (with its recently launched “dm?med” platform) and Rossmann (building its own online dispensary) are encroaching on Redcare’s OTC turf. The e?pharmacy operator responded by slashing its medium?term OTC margin target from above 8% to more than 5%. For 2026 as a whole, management expects a group?wide adjusted EBITDA margin of at least 2.5%. That is a sobering reality check for a stock that once traded at nose?bleed multiples.

Should investors sell immediately? Or is it worth buying Redcare Pharmacy?

The Apothekenreform: Double?Edged Sword or Tailwind?

The market’s biggest uncertainty is the Apothekenversorgung-Weiterentwicklungsgesetz passed by the Bundestag on May 22, 2026. The law, backed by the CDU/CSU and SPD, is set to take effect this summer. Its net effect on Redcare is ambiguous. Each physical pharmacy that closes — and hundreds are expected to shutter under the new regime — diverts prescription volume to digital channels. With a 67% share of Germany’s online Rx market, Redcare stands to gobble up the lion’s share of that displaced demand. However, the law also threatens to impose stricter requirements on mail?order dispensaries regarding temperature control, documentation, and contractual standards — provisions that could raise compliance costs. The market has so far priced in the worst?case scenario, but the final shape of the rules still hinges on a vote in the Bundesrat.

Boardroom Shake?Up and Tech Upgrade

While the policy debate swirls, Redcare is quietly overhauling its senior leadership and back?end infrastructure. Chief Commercial Officer Dirk Brüse is leaving the company, and three new supervisory board members — Anja Hendel, Max Müller, and Peter Schmid von Linstow — were elected in April, replacing three long?standing directors who had served since the 2016 IPO. On the technology front, Redcare has digitised its access to the Telematikinfrastruktur by replacing the physical institutional card with a fully digital identity, developed in partnership with ehex and D?Trust. The new HSM?B technology promises greater speed, stability, and scalability. The existing CardLink licence runs until January 2027, giving the group ample time to transition to a new infrastructure standard that gematik plans to roll out by end?2026.

Analyst Divergence: Deep Value or Value Trap?

The valuation gap between market price and analyst estimates remains cavernous. Six independent research houses put the average fair value at €79.92, implying roughly 80% upside from current levels. Deutsche Bank’s Jan Koch is even more bullish, reiterating a €99 price target after meeting management at the dbAccess European Champions Conference. Koch argues that the current valuation — about €44 per share — already reflects the margin compression and regulatory risks, leaving room for a significant re?rating once the pharmacy law is clarified and operating momentum continues into the second quarter.

The Next Catalyst: Half?Year Report in July

Redcare will publish its second?quarter results on July 29, 2026. That report will be the first hard test of whether the first?quarter revenue acceleration can be sustained under the new regulatory regime and whether margins are stabilising. Until then, the stock is likely to oscillate between political headlines and technical support levels — but for investors who can stomach the volatility, the disconnect between a 60% share?price decline and a 55% prescription?growth rate may be too large to ignore.

Ad

Redcare Pharmacy Stock: New Analysis - 30 May

Fresh Redcare Pharmacy information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Redcare Pharmacy analysis...

en | NL0012044747 | REDCARE | boerse | 69445774 |